

# An exploratory clinical study on the safety and efficacy of aurantii fructus immaturus flavonoid extract tablets (Aolanti) in the treatment of functional dyspepsia

<b>Submission date</b> 24/02/2025	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 09/03/2025	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 06/03/2025	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

This study aimed to evaluate the safety and effectiveness of Aurantii Fructus Immaturus Flavonoid Extract Tablets (Aolanti) in treating functional dyspepsia (FD), a chronic digestive disorder that causes pain and discomfort in the upper abdomen. The goal was to determine the optimal dosage for Phase III clinical trials.

### Who can participate?

Patients aged 18 to 65 years with functional dyspepsia

### What does the study involve?

Participants were divided into four groups: high-dose, medium-dose, low-dose, and placebo groups. The treatment duration was 28 days, with a follow-up period of 28 days for participants whose symptoms resolved.

### What are the possible benefits and risks of participating?

Potential benefits included the alleviation of FD symptoms. Potential risks involved possible adverse drug reactions, although the study results indicated that the drug was well-tolerated with a favorable safety profile.

### Where is the study run from?

Jiangxi Qingfeng Pharmaceutical Co., Ltd (China)

### When is the study starting and how long is it expected to run for?

June 2011 to December 2012

### Who is funding the study?

Jiangxi Qingfeng Pharmaceutical Co., Ltd (China)

Who is the main contact?  
Xiaonan Yang, yangxxnan@163.com

## Contact information

### Type(s)

Public

### Contact name

Ms Tiancheng Qi

### Contact details

10th Floor, Block A, Building 2  
Shenzhen Bay Science and Technology Ecological Park  
Nanshan District  
Shenzhen  
China  
518063  
+86 (0)18588477550  
qitiancheng@qfyy.com.cn

### Type(s)

Scientific

### Contact name

Ms Xiaolei Bi

### Contact details

9th Floor, Building 3  
Kunsha Center  
No. 16 Xinyuanli  
Chaoyang District  
Beijing  
China  
100027  
+86 (0)13811657829  
bixiaolei@qfyy.com.cn

### Type(s)

Principal investigator

### Contact name

Ms Xiaonan Yang

### Contact details

West China Hospital of Sichuan University  
No. 37, Guoxue Alley  
Wuhou District  
Chengdu  
China

610041  
+86 (0)13608000318  
yangxxnan@163.com

## **Additional identifiers**

### **Clinical Trials Information System (CTIS)**

Nil known

### **ClinicalTrials.gov (NCT)**

Nil known

### **Protocol serial number**

Nil known

## **Study information**

### **Scientific Title**

A multicenter, randomized, double-blind, placebo-controlled, dose-exploratory clinical study on the safety and efficacy of aurantii fructus immaturus flavonoid extract tablets (Aolanti) in the treatment of functional dyspepsia

### **Study objectives**

A placebo-controlled study to evaluate the efficacy and safety of high, medium, and low doses of Aurantii Fructus Immaturus Flavonoid Extract Tablets (Aolanti) in the treatment of functional dyspepsia, and to explore the optimal dosage for Phase III clinical trials.

### **Ethics approval required**

Ethics approval required

### **Ethics approval(s)**

approved 28/07/2011, Clinical Trial Ethics Committee of West China Hospital of Sichuan University (No. 37 Guoxue Alley, Wuhou District, Chengdu, 610041, China; +86 (0)28 85422114; hxjj@cd120.com), ref: 2008L04094

### **Study design**

Stratified block randomized double-blind placebo-parallel-controlled multicenter clinical study

### **Primary study design**

Interventional

### **Study type(s)**

Treatment, Safety, Efficacy

### **Health condition(s) or problem(s) studied**

Functional dyspepsia

### **Interventions**

Patients were divided into one of the experimental groups (high-dose group, medium-dose group, low-dose group) or the control group. A central block randomization method was

employed. Using the SAS statistical analysis system, a random arrangement of treatments (experimental drug and control drug) for 400 subjects was generated. Specifically, a sequence of serial numbers from 001 to 400 was created, with each number corresponding to a treatment allocation. Each center was assigned a continuous block of drug codes (exceptions may occur due to case reallocation caused by progress-related reasons).

**Experimental Drug:**

Aurantii Fructus Immaturus Flavonoid Extract Tablets (Aolanti), specification: 0.29 g/tablet, provided by Jiangxi Qingfeng Pharmaceutical Co., Ltd., batch number: 20110605.

**Control Drug:**

Aurantii Fructus Immaturus Flavonoid Extract Tablets (Aolanti) placebo, specification: 0.29 g/tablet, provided by Jiangxi Qingfeng Pharmaceutical Co., Ltd., batch number: 20110605.

**Dosage and Administration:**

High-dose group: four tablets of Aurantii Fructus Immaturus Flavonoid Extract Tablets (Aolanti) per dose, taken with warm water half an hour before meals, three times a day.

Medium-dose group: three tablets of Aurantii Fructus Immaturus Flavonoid Extract Tablets (Aolanti) + one placebo tablet per dose, taken with warm water half an hour before meals, three times a day.

Low-dose group: two tablets of Aurantii Fructus Immaturus Flavonoid Extract Tablets (Aolanti) + two placebo tablets per dose, taken with warm water half an hour before meals, three times a day.

Placebo group: four placebo tablets per dose, taken with warm water half an hour before meals, three times a day.

**Observation Period:**

Treatment Duration: 28 days.

Follow-up: 28 days (only patients with all four symptoms resolved will undergo follow-up after discontinuation of the medication).

**Intervention Type**

Drug

**Phase**

Phase II

**Drug/device/biological/vaccine name(s)**

Aurantii Fructus Immaturus Flavonoid Extract Tablets (Aolanti)

**Primary outcome(s)**

The percentage of disappearance of the four Western medical symptoms of functional dyspepsia (postprandial fullness, early satiation, epigastric burning, and epigastric pain) after 4 weeks of medication.

1. Functional dyspepsia symptoms (postprandial fullness, early satiation, epigastric burning) are scored as follows:

0 points: No symptoms

1 point: Mild symptoms that do not affect daily life

2 points: Moderate symptoms that do not significantly affect daily life

3 points: Persistent symptoms that significantly affect daily life

2. For epigastric pain, the Visual Analog Scale (VAS) is used:

A 10-cm straight line is employed, where the 0 cm end represents "no pain" and the 10 cm end represents "the most severe pain." Patients mark the point on the line that corresponds to their level of pain.

### **Key secondary outcome(s)**

Gastric emptying assessed using radionuclide imaging: for selected centers (West China Hospital of Sichuan University and Xiangya Hospital of Central South University), radionuclide imaging is used to assess gastric emptying function. The 2-hour gastric emptying rate and half-emptying time are observed. The test is conducted and recorded once before medication and once after 28 days of medication. The 2-hour gastric emptying rate and half-emptying time (radionuclide imaging) are compared between groups.

### **Completion date**

31/12/2012

## **Eligibility**

### **Key inclusion criteria**

1. Age  $\geq 18$  years and  $\leq 65$  years, regardless of gender
2. Voluntarily participate and sign the written informed consent form
3. Meet the diagnostic criteria for functional dyspepsia
4. Discontinuation of other prokinetic agents, gastroprotective agents, or acid-suppressing drugs for at least 4 weeks prior to enrollment

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Lower age limit**

18 years

### **Upper age limit**

65 years

### **Sex**

All

### **Total final enrolment**

399

### **Key exclusion criteria**

1. Individuals with organic diseases such as esophagitis, atrophic gastritis, gastric and duodenal ulcers, erosions, bleeding, tumors, etc
2. Individuals with organic diseases of the liver, gallbladder, or pancreas
3. Individuals with diabetes, kidney disease, connective tissue disease, or psychiatric disorders

4. Individuals with severe primary diseases of the heart, brain, lungs, kidneys, hematopoietic system, or endocrine system
5. Individuals with a history of abdominal surgery
6. Individuals with renal insufficiency, with creatinine (Cr) levels above the upper limit of normal
7. Individuals with hepatic insufficiency, with AST and/or ALT levels 1.5 times the upper limit of normal
8. Pregnant women, those with pregnancy intentions, or women who are breastfeeding
9. Individuals with mental or legal disabilities
10. Individuals who have participated in other drug clinical trials within the 3 months prior to this trial

**Date of first enrolment**

19/10/2011

**Date of final enrolment**

25/09/2012

## **Locations**

**Countries of recruitment**

China

**Study participating centre**

**West China Hospital of Sichuan University**

No. 37, Guoxue Alley

Wuhou District

Chengdu

China

610041

**Study participating centre**

**Affiliated Hospital of Chengdu University of Traditional Chinese Medicine**

No. 39, Shierqiao Road

Jinniu District

Chengdu

China

610072

**Study participating centre**

**The First Affiliated Hospital of Hunan University of Chinese Medicine**

No. 95, Shaoshan Middle Road

Furong District

Changsha

China

410007

**Study participating centre****Xiangya Hospital of Central South University**

No. 87, Xiangya Road

Kaifu District

Changsha

China

410008

**Study participating centre****Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine**

No. 445, Bayi Avenue

Xihu District

Nanchang

China

330006

**Study participating centre****Tianjin University of Traditional Chinese Medicine First Affiliated Hospital**

No. 314, Anshan West Road

Nankai District

Tianjin

China

300193

**Study participating centre****Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital**

No. 816, Zhenli Road

Hebei District

Tianjin

China

300150

**Sponsor information****Organisation**

Jiangxi Qingfeng Pharmaceutical Co., Ltd.

# Funder(s)

## Funder type

Industry

## Funder Name

Jiangxi Qingfeng Pharmaceutical Co., Ltd.

# Results and Publications

## Individual participant data (IPD) sharing plan

The aggregated research data will be stored by the sponsor as required. The original research data will be retained at each research center in accordance with regulations. Interested parties may submit a request to the sponsor as needed, and the sponsor will provide relevant content based on actual circumstances.(Contact: Qi,qitiancheng@qfyy.com.cn)

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes